Scarica l'app Stockscreener
1.40
2.10%
-0.03
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PYXS Giù?
Forum
Previsione
Pyxis Oncology Inc Borsa (PYXS) Ultime notizie
Pyxis Oncology director Humphrey sells $15917 in shares By Investing.com - Investing.com Australia
Pyxis Oncology (PYXS) director receives 45,867 stock options at $1.36 strike - Stock Titan
Pyxis Oncology (PYXS) grants director Jakob Dupont 45,867 stock options - Stock Titan
Executive at Pyxis Oncology (PYXS) receives new option and RSU equity grants - Stock Titan
Pyxis Oncology director Humphrey sells $15917 in shares - Investing.com
Pyxis Oncology (PYXS) director receives grant of 45,867 stock options - Stock Titan
[Form 4] Pyxis Oncology, Inc. Insider T... - Stock Titan
Director at Pyxis Oncology (PYXS) receives grant of 45,867 stock options - Stock Titan
Pyxis Oncology (NASDAQ:PYXS) Director Rachel Humphrey Sells 13,896 Shares - MarketBeat
Pyxis Oncology (PYXS) director sells 15,496 shares under 10b5-1 plan - Stock Titan
FY2029 EPS Estimates for Pyxis Oncology Lifted by Analyst - MarketBeat
LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $5 - Moomoo
A Quick Look at Today's Ratings for Pyxis Oncology(PYXS.US), With a Forecast Between $5 to $7 - Moomoo
Stifel Nicolaus Lowers Pyxis Oncology (NASDAQ:PYXS) Price Target to $8.00 - MarketBeat
Pyxis Oncology (NASDAQ:PYXS) Given Buy Rating at HC Wainwright - MarketBeat
Guggenheim reiterates Buy on Pyxis Oncology stock ahead of trial data By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Buy on Pyxis Oncology stock, $7 target - Investing.com
Pyxis Oncology (PYXS) Rating Reiterated as Buy by HC Wainwright & Co. | PYXS Stock News - GuruFocus
RBC Capital Initiates Pyxis Oncology(PYXS.US) With Buy Rating, Announces Target Price $5 - Moomoo
Stifel cuts Pyxis Oncology stock price target on financing assumptions - Investing.com
Pyxis Oncology Reports 2025 Financial Results, Advances MICVO Cancer Trials, and Announces New Leadership - Minichart
William Blair reiterates Pyxis Oncology stock rating on trial pace By Investing.com - Investing.com South Africa
William Blair reiterates Pyxis Oncology stock rating on trial pace - Investing.com UK
Jefferies raises Pyxis Oncology stock price target on drug data By Investing.com - Investing.com Australia
Jefferies raises Pyxis Oncology stock price target on drug data - Investing.com
MicuRx Pharmaceuticals: Advancing Novel ADC Therapy MICVO for Difficult-to-Treat Head and Neck Cancer – Pipeline, Strategy, and Risks Overview - Minichart
Pyxis Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Pyxis Oncology (NASDAQ:PYXS) Posts Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Pyxis Oncology Reports Q4 Results, Advances MICVO Program - TipRanks
Pyxis Oncology 10-K: Revenue $13.9M; Net loss $(79.6)M - TradingView
Pyxis Oncology (PYXS) highlights MICVO ADC progress in head and neck cancer - Stock Titan
Pyxis Oncology (NASDAQ: PYXS) details 2025 results and MICVO head & neck cancer data - Stock Titan
Pyxis Oncology 2025 net loss widens on higher R&D spend - TradingView
BRIEF-Pyxis Oncology FY Net Income USD -79.621 Million - TradingView
Pyxis fills head and neck cancer study, says cash lasts into Q4 - Stock Titan
PYXS Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
PYXS Stock Price, Quote & Chart | PYXIS ONCOLOGY INC (NASDAQ:PYXS) - ChartMill
PYXS SEC FilingsPyxis Oncology, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Pyxis Oncology (NASDAQ:PYXS) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Pyxis Oncology Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
Pyxis Oncology (PYXS) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Pyxis Oncology (NASDAQ:PYXS) Stock Rating Upgraded by Wall Street Zen - Defense World
PYXS Earnings History & Surprises | EPS & Revenue Results | PYXIS ONCOLOGY INC (NASDAQ:PYXS) - ChartMill
Pyxis Oncology (NASDAQ:PYXS) Upgraded at Wall Street Zen - MarketBeat
PYXS Technical Analysis & ETF Price Forecast - Intellectia AI
Will Pyxis Oncology Inc stock benefit from M A2025 Growth vs Value & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
PYXS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Can Pyxis Oncology Inc. expand its profit marginsWeekly Trade Review & Low Drawdown Investment Ideas - mfd.ru
PYXS Should I Buy - Intellectia AI
Can Pyxis Oncology Inc. stock hit record highs againWeekly Risk Report & AI Powered Buy/Sell Recommendations - mfd.ru
Street Watch: Can Pyxis Oncology Inc sustain its profitabilityJuly 2025 News Drivers & Fast Gain Stock Tips - baoquankhu1.vn
PYXS PE Ratio & Valuation, Is PYXS Overvalued - Intellectia AI
Can Pyxis Oncology Inc. sustain its profitabilityJuly 2025 Fed Impact & Capital Protection Trade Alerts - mfd.ru
What catalysts could drive Pyxis Oncology Inc. stock higherJuly 2025 Summary & Risk Managed Trade Strategies - mfd.ru
Pyxis Oncology Announces Interim CEO Amid Leadership Transition - The Globe and Mail
Pyxis Oncology (PYXS) taps board member Thomas Civik as interim CEO in leadership shift - Stock Titan
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Pyxis Oncology (PYXS) - The Globe and Mail
Pyxis Oncology appoints Thomas Civik as interim CEO By Investing.com - Investing.com Nigeria
Pyxis Oncology, Inc. Announces Chief Executive Officer Changes, Effective February 3, 2026 - marketscreener.com
Pyxis Oncology names Thomas Civik as interim CEO - marketscreener.com
Pyxis Oncology Appoints Thomas Civik as Interim CEO - citybiz
0.99%
3.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):